Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …

MacroH2A has established tumour suppressive functions in melanoma and other cancers,
but an unappreciated role in the tumour microenvironment. Using an autochthonous …

Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal
adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK …

Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate
the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX …

Although systemic chemotherapy remains the standard of care for TNBC, even combination
chemotherapy is often ineffective. The identification of biomarkers for differential …

Patient‐derived tumor xenograft (PDX) models, a method involving the surgical extraction of
tumor tissues from cancer patients and subsequent transplantation into immunodeficient …

Breast cancer is well-known to be a highly heterogenous disease. This facet of cancer
makes finding a research model that mirrors the disparate intrinsic features challenging …

While large publicly available cancer cell line databases are invaluable for preclinical drug
discovery and biomarker development, the association between homologous recombination …